Novel Approaches to Epigenetic Therapies: From Drug Combinations to Epigenetic Editing
Abstract
:1. Introduction
2. DNMT Inhibitors
3. Drugs Targeting Histone Modifications
3.1. Histone Acetylation Modifiers
3.2. Targeting Histone Methyltransferases
4. Combining DNMTi and HDACi
5. Epigenetic Drugs and Chemotherapy
6. Epigenetic Drugs in Combination with Immunotherapy
7. Multitargeting Epigenetic Drugs
8. Targeting the Metabolic Causes of Epigenetic Changes—The Role of Oncometabolites
9. Epigenetic Editing
10. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Esteller, M. Epigenetics in cancer. N. Engl. J. Med. 2008, 358, 1148–1159. [Google Scholar] [CrossRef] [PubMed]
- Simó-Riudalbas, L.; Esteller, M. Cancer genomics identifies disrupted epigenetic genes. Hum. Genet. 2014, 133, 713–725. [Google Scholar] [CrossRef] [PubMed]
- Jones, P.A.; Issa, J.P.; Baylin, S. Targeting the cancer epigenome for therapy. Nat. Rev. Genet. 2016, 17, 630–641. [Google Scholar] [CrossRef] [PubMed]
- Ahuja, N.; Sharma, A.R.; Baylin, S.B. Epigenetic Therapeutics: A New Weapon in the War against Cancer. Annu. Rev. Med. 2016, 67, 73–89. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Simó-Riudalbas, L.; Esteller, M. Targeting the histone orthography of cancer: Drugs for writers, erasers and readers. Br. J. Pharmacol. 2015, 172, 2716–2732. [Google Scholar] [CrossRef] [Green Version]
- Inbar-Feigenberg, M.; Choufani, S.; Butcher, D.T.; Roifman, M.; Weksberg, R. Basic concepts of epigenetics. Fertil. Steril. 2013, 99, 607–615. [Google Scholar] [CrossRef]
- Ferreira, H.J.; Esteller, M. CpG Islands in Cancer: Heads, Tails, and Sides. Methods Mol. Biol. 2018, 1766, 49–80. [Google Scholar] [CrossRef]
- Sleutels, F.; Barlow, D.P. The origins of genomic imprinting in mammals. Adv. Genet. 2002, 46, 119–163. [Google Scholar] [CrossRef]
- Ho, A.S.; Turcan, S.; Chan, T.A. Epigenetic therapy: Use of agents targeting deacetylation and methylation in cancer management. Onco Targets Ther. 2013, 6, 223–232. [Google Scholar] [CrossRef]
- Schübeler, D. Function and information content of DNA methylation. Nature 2015, 517, 321–326. [Google Scholar] [CrossRef]
- Liao, J.; Karnik, R.; Gu, H.; Ziller, M.J.; Clement, K.; Tsankov, A.M.; Akopian, V.; Gifford, C.A.; Donaghey, J.; Galonska, C.; et al. Targeted disruption of DNMT1, DNMT3A and DNMT3B in human embryonic stem cells. Nat. Genet. 2015, 47, 469–478. [Google Scholar] [CrossRef] [Green Version]
- Nunes, S.P.; Henrique, R.; Jerónimo, C.; Paramio, J.M. DNA Methylation as a Therapeutic Target for Bladder Cancer. Cells 2020, 9, 1850. [Google Scholar] [CrossRef] [PubMed]
- Lyko, F. The DNA methyltransferase family: A versatile toolkit for epigenetic regulation. Nat. Rev. Genet. 2018, 19, 81–92. [Google Scholar] [CrossRef]
- Majchrzak-Celińska, A.; Dybska, E.; Barciszewska, A.M. DNA methylation analysis with methylation-sensitive high-resolution melting (MS-HRM) reveals gene panel for glioma characteristics. CNS Neurosci. Ther. 2020, 26, 1303–1314. [Google Scholar] [CrossRef]
- Majchrzak-Celińska, A.; Zielińska-Przyjemska, M.; Wierzchowski, M.; Kleszcz, R.; Studzińska-Sroka, E.; Kaczmarek, M.; Paluszczak, J.; Cielecka-Piontek, J.; Krajka-Kuźniak, V. Methoxy-stilbenes downregulate the transcription of Wnt/β-catenin-dependent genes and lead to cell cycle arrest and apoptosis in human T98G glioblastoma cells. Adv. Med. Sci. 2020, 66, 6–20. [Google Scholar] [CrossRef] [PubMed]
- Majchrzak-Celińska, A.; Baer-Dubowska, W. Pharmacoepigenetics: An element of personalized therapy? Expert Opin. Drug Metab. Toxicol. 2016, 13, 387–398. [Google Scholar] [CrossRef] [PubMed]
- Majchrzak-Celińska, A.; Paluszczak, J.; Kleszcz, R.; Magiera, M.; Barciszewska, A.-M.; Nowak, S.; Baer-Dubowska, W. Detection of MGMT, RASSF1A, p15INK4B, and p14ARF promoter methylation in circulating tumor-derived DNA of central nervous system cancer patients. J. Appl. Genet. 2013, 54, 335–344. [Google Scholar] [CrossRef] [Green Version]
- Majchrzak-Celińska, A.; Słocińska, M.; Barciszewska, A.M.; Nowak, S.; Baer-Dubowska, W. Wnt pathway antagonists, SFRP1, SFRP2, SOX17, and PPP2R2B, are methylated in gliomas and SFRP1 methylation predicts shorter survival. J. Appl. Genet. 2015, 57, 189–197. [Google Scholar] [CrossRef] [Green Version]
- Majchrzak-Celińska, A.; Paluszczak, J.; Szalata, M.; Barciszewska, A.M.; Nowak, S.; Kleszcz, R.; Sherba, A.; Baer-Dubowska, W. The methylation of a panel of genes differentiates low-grade from high-grade gliomas. Tumor Biol. 2015, 36, 3831–3841. [Google Scholar] [CrossRef]
- Cheng, Y.; He, C.; Wang, M.; Ma, X.; Mo, F.; Yang, S.; Han, J.; Wei, X. Targeting epigenetic regulators for cancer therapy: Mechanisms and advances in clinical trials. Signal Transduct. Target. Ther. 2019, 4, 62. [Google Scholar] [CrossRef] [Green Version]
- Jones, P.A.; Ohtani, H.; Chakravarthy, A.; De Carvalho, D.D. Epigenetic therapy in immune-oncology. Nat. Rev. Cancer 2019, 19, 151–161. [Google Scholar] [CrossRef] [PubMed]
- Constantinides, P.G.; Taylor, S.M.; Jones, P.A. Phenotypic conversion of cultured mouse embryo cells by aza pyrimidine nucleosides. Dev. Biol. 1978, 66, 57–71. [Google Scholar] [CrossRef]
- Santi, D.V.; Norment, A.; Garrett, C.E. Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine. Proc. Natl. Acad. Sci. USA 1984, 81, 6993–6997. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chen, L.; MacMillan, A.M.; Chang, W.; Ezaz-Nikpay, K.; Lane, W.S.; Verdine, G.L. Direct identification of the active-site nucleophile in a DNA (cytosine-5)-methyltransferase. Biochemistry 1991, 30, 11018–11025. [Google Scholar] [CrossRef]
- Ishak, C.A.; Classon, M.; De Carvalho, D.D. Deregulation of retroelements as an emerging therapeutic opportunity in cancer. Trends Cancer 2018, 4, 583–597. [Google Scholar] [CrossRef]
- Roulois, D.; Loo, Y.H.; Singhania, R.; Wang, Y.; Danesh, A.; Shen, S.Y.; Han, H.; Liang, G.; Jones, P.A.; Pugh, T.J.; et al. DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts. Cell 2015, 62, 961–973. [Google Scholar] [CrossRef] [Green Version]
- Chiappinelli, K.B.; Strissel, P.L.; Desrichard, A.; Li, H.; Henke, C.; Akman, B.; Hein, A.; Rote, N.S.; Cope, L.M.; Snyder, A.; et al. Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. Cell 2015, 162, 974–986. [Google Scholar] [CrossRef] [Green Version]
- Wong, K.K.; Lawrie, C.H.; Green, T.M. Oncogenic Roles and Inhibitors of DNMT1, DNMT3A, and DNMT3B in Acute Myeloid Leukaemia. Biomark. Insights 2019, 14, 1177271919846454. [Google Scholar] [CrossRef]
- Issa, J.J.; Roboz, G.; Rizzieri, D.; Jabbour, E.; Stock, W.; O’Connell, C.; Yee, K.; Tibes, R.; Griffiths, E.A.; Walsh, K.; et al. Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: A multicentre, randomised, dose-escalation phase 1 study. Lancet Oncol. 2015, 16, 1099–1110. [Google Scholar] [CrossRef] [Green Version]
- Zwergel, C.; Schnekenburger, M.; Sarno, F.; Battistelli, C.; Manara, M.C.; Stazi, G.; Mazzone, R.; Fioravanti, R.; Gros, C.; Ausseil, F.; et al. Identification of a novel quinoline-based DNA demethylating compound highly potent in cancer cells. Clin. Epigenetics 2019, 11, 68. [Google Scholar] [CrossRef] [Green Version]
- Zwergel, C.; Valente, S.; Mai, A. DNA Methyltransferases Inhibitors from Natural Sources. Curr. Top. Med. Chem. 2016, 16, 680–696. [Google Scholar] [CrossRef] [PubMed]
- Akone, S.H.; Ntie-Kang, F.; Stuhldreier, F.; Ewonkem, M.B.; Noah, A.M.; Mouelle, S.E.M.; Müller, R. Natural Products Impacting DNA Methyltransferases and Histone Deacetylases. Front. Pharmacol. 2020, 11, 992. [Google Scholar] [CrossRef] [PubMed]
- Bannister, A.J.; Kouzarides, T. Regulation of chromatin by histone modifications. Cell Res. 2011, 21, 95–381. [Google Scholar] [CrossRef] [PubMed]
- Lu, Y.; Chan, Y.T.; Tan, H.Y.; Li, S.; Wang, N.; Feng, Y. Epigenetic regulation in human cancer: The potential role of epi-drug in cancer therapy. Mol. Cancer 2020, 19, 79. [Google Scholar] [CrossRef] [PubMed]
- Hyun, K.; Jeon, J.; Park, K.; Kim, J. Writing, erasing and reading histone lysine methylations. Exp. Mol. Med. 2017, 49, e324. [Google Scholar] [CrossRef] [Green Version]
- Greer, E.L.; Shi, Y. Histone methylation: A dynamic mark in health, disease and inheritance. Nat. Rev. Genet. 2012, 13, 343–357. [Google Scholar] [CrossRef] [Green Version]
- Song, Y.; Wu, F.; Wu, J. Targeting histone methylation for cancer therapy: Enzymes, inhibitors, biological activity and perspectives. J. Hematol. Oncol. 2016, 9, 49. [Google Scholar] [CrossRef] [Green Version]
- Hontecillas-Prieto, L.; Flores-Campos, R.; Silver, A.; de Álava, E.; Hajji, N.; García-Domínguez, D.J. Synergistic Enhancement of Cancer Therapy Using HDAC Inhibitors: Opportunity for Clinical Trials. Front. Genet. 2020, 11, 578011. [Google Scholar] [CrossRef]
- Feng, D.; Wu, J.; Tian, Y.; Zhou, H.; Zhou, Y.; Hu, W.; Zhao, W.; Wei, H.; Ling, B.; Ma, C. Targeting of histone deacetylases to reactivate tumour suppressor genes and its therapeutic potential in a human cervical cancer xenograft model. PLoS ONE 2013, 8, e80657. [Google Scholar] [CrossRef] [Green Version]
- Haberland, M.; Montgomery, R.L.; Olson, E.N. The many roles of histone deacetylases in development and physiology: Implications for disease and therapy. Nat. Rev. Genet. 2009, 10, 32–42. [Google Scholar] [CrossRef]
- Ceccacci, E.; Minucci, S. Inhibition of histone deacetylases in cancer therapy: Lessons from leukaemia. Br. J. Cancer 2016, 114, 605–611. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mrakovcic, M.; Fröhlich, L.F. Molecular Determinants of Cancer Therapy Resistance to HDAC Inhibitor-Induced Autophagy. Cancers 2019, 12, 109. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Patnaik, S. Drugs Targeting Epigenetic Modifications and Plausible Therapeutic Strategies against Colorectal Cancer. Front. Pharmacol. 2019, 10, 588. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Banik, D.; Moufarrij, S.; Villagra, A. Immunoepigenetics Combination Therapies: An Overview of the Role of HDACs in Cancer Immunotherapy. Int. J. Mol. Sci. 2019, 20, 2241. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mann, B.S.; Johnson, J.R.; Cohen, M.H.; Justice, R.; Pazdur, R. FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 2007, 12, 1247–1252. [Google Scholar] [CrossRef] [PubMed]
- Wang, P.; Wang, Z.; Liu, J. Role of HDACs in normal and malignant hematopoiesis. Mol. Cancer 2020, 19, 5. [Google Scholar] [CrossRef] [Green Version]
- Ganesan, A.; Arimondo, P.B.; Rots, M.G.; Jeronimo, C.; Berdasco, M. The timeline of epigenetic drug discovery: From reality to dreams. Clin. Epigenetics 2019, 11, 174. [Google Scholar] [CrossRef] [Green Version]
- De Lera, A.R.; Ganesan, A. Epigenetic polypharmacology: From combination therapy to multitargeted drugs. Clin. Epigenetics 2016, 8, 105. [Google Scholar] [CrossRef] [Green Version]
- Romanelli, A.; Stazi, G.; Fioravanti, R.; Zwergel, C.; Di Bello, E.; Pomella, S.; Perrone, C.; Battistelli, C.; Strippoli, R.; Tripodi, M.; et al. Design of First-in-Class Dual EZH2/HDAC Inhibitor: Biochemical Activity and Biological Evaluation in Cancer Cells. ACS Med. Chem. Lett. 2020, 11, 977–983. [Google Scholar] [CrossRef]
- Targeting chromatin. Nat. Struct. Mol. Biol. 2019, 26, 841. [CrossRef] [Green Version]
- Marcos-Villar, L.; Nieto, A. The DOT1L inhibitor Pinometostat decreases the host-response against infections: Considerations about its use in human therapy. Sci. Rep. 2019, 9, 16862. [Google Scholar] [CrossRef] [PubMed]
- Waters, N.J. Preclinical Pharmacokinetics and Pharmacodynamics of Pinometostat (EPZ-5676), a First-in-Class, Small Molecule S-Adenosyl Methionine Competitive Inhibitor of DOT1L. Eur. J. Drug. Metab. Pharmacokinet. 2017, 42, 891–901. [Google Scholar] [CrossRef] [PubMed]
- Connolly, R.M.; Li, H.; Jankowitz, R.C.; Zhang, Z.; Rudek, M.A.; Jeter, S.C.; Slater, S.A.; Powers, P.; Wolff, A.C.; Fetting, J.H.; et al. Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study. Clin. Cancer Res. 2017, 23, 2691–2701. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Juergens, R.A.; Wrangle, J.; Vendetti, F.P.; Murphy, S.C.; Zhao, M.; Coleman, B.; Sebree, R.; Rodgers, K.; Hooker, C.M.; Franco, N.; et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov. 2011, 1, 598–607. [Google Scholar] [CrossRef] [Green Version]
- Lu, Z.; Zou, J.; Li, S.; Topper, M.J.; Tao, Y.; Zhang, H.; Jiao, X.; Xie, W.; Kong, X.; Vaz, M.; et al. Epigenetic therapy inhibits metastases by disrupting premetastatic niches. Nature 2020, 579, 284–290. [Google Scholar] [CrossRef]
- Moufarrij, S.; Srivastava, A.; Gomez, S.; Hadley, M.; Palmer, E.; Austin, P.T.; Chisholm, S.; Roche, K.; Yu, A.; Li, J. Combining DNMT and HDAC6 inhibitors increases anti-tumor immune signaling and decreases tumor burden in ovarian cancer. Sci. Rep. 2020, 10, 3470. [Google Scholar] [CrossRef] [Green Version]
- Li, J.; Hao, D.; Wang, L.; Wang, H.; Wang, Y.; Zhao, Z.; Li, P.; Deng, C.; Di, L.J. Epigenetic targeting drugs potentiate chemotherapeutic effects in solid tumor therapy. Sci. Rep. 2017, 7, 4035. [Google Scholar] [CrossRef] [Green Version]
- Schneider, B.J.; Shah, M.A.; Klute, K.; Ocean, A.; Popa, E.; Altorki, N.; Lieberman, M.; Schreiner, A.; Yantiss, R.; Christos, P.J.; et al. Phase I Study of Epigenetic Priming with Azacitidine Prior to Standard Neoadjuvant Chemotherapy for Patients with Resectable Gastric and Esophageal Adenocarcinoma: Evidence of Tumor Hypomethylation as an Indicator of Major Histopathologic Response. Clin. Cancer Res. 2017, 23, 2673–2680. [Google Scholar] [CrossRef] [Green Version]
- Moro, H.; Hattori, N.; Nakamura, Y.; Kimura, K.; Imai, T.; Maeda, M.; Yashiro, M.; Ushijima, T. Epigenetic priming sensitizes gastric cancer cells to irinotecan and cisplatin by restoring multiple pathways. Gastric Cancer 2020, 23, 105–115. [Google Scholar] [CrossRef]
- Zeller, C.; Dai, W.; Steele, N.L.; Siddiq, A.; Walley, A.J.; Wilhelm-Benartzi, C.S.; Rizzo, S.; van der Zee, A.; Plumb, J.A.; Brown, R. Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling. Oncogene 2012, 31, 4567–4576. [Google Scholar] [CrossRef] [Green Version]
- Qin, T.; Si, J.; Raynal, N.J.; Wang, X.; Gharibyan, V.; Ahmed, S.; Hu, X.; Jin, C.; Lu, Y.; Shu, J.; et al. Epigenetic synergy between decitabine and platinum derivatives. Clin. Epigenetics 2015, 7, 97. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Coronel, J.; Cetina, L.; Pacheco, I.; Trejo-Becerril, C.; González-Fierro, A.; de la Cruz-Hernandez, E.; Perez-Cardenas, E.; Taja-Chayeb, L.; Arias-Bofill, D.; Candelaria, M.; et al. A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Prelim. Results Med. Oncol. 2011, 28, 540–546. [Google Scholar] [CrossRef] [PubMed]
- Wasim, L.; Chopra, M. Synergistic anticancer effect of panobinostat and topoisomerase inhibitors through ROS generation and intrinsic apoptotic pathway induction in cervical cancer cells. Cell. Oncol. 2018, 41, 201–212. [Google Scholar] [CrossRef]
- Greve, G.; Schiffmann, I.; Lübbert, M. Epigenetic priming of non-small cell lung cancer cell lines to the antiproliferative and differentiating effects of all-trans retinoic acid. J. Cancer Res. Clin. Oncol. 2015, 141, 2171–2180. [Google Scholar] [CrossRef] [PubMed]
- Bruzzese, F.; Pucci, B.; Milone, M.R.; Ciardiello, C.; Franco, R.; Chianese, M.I.; Rocco, M.; Di Gennaro, E.; Leone, A.; Luciano, A.; et al. Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways. Cell Death Dis. 2013, 4, e878. [Google Scholar] [CrossRef]
- Gao, L.; Gao, M.; Yang, G.; Tao, Y.; Kong, Y.; Yang, R.; Meng, X.; Ai, G.; Wei, R.; Wu, H.; et al. Synergistic Activity of Carfilzomib and Panobinostat in Multiple Myeloma Cells via Modulation of ROS Generation and ERK1/2. BioMed Res. Int. 2015, 2015, 459052. [Google Scholar] [CrossRef]
- Del Bufalo, D.; Desideri, M.; De Luca, T.; Di Martile, M.; Gabellini, C.; Monica, V.; Busso, S.; Eramo, A.; De Maria, R.; Milella, M.; et al. Histone deacetylase inhibition synergistically enhances pemetrexed cytotoxicity through induction of apoptosis and autophagy in non-small cell lung cancer. Mol. Cancer 2014, 9, 230. [Google Scholar] [CrossRef] [Green Version]
- Di Martile, M.; Desideri, M.; Tupone, M.G.; Buglioni, S.; Antoniani, B.; Mastroiorio, C.; Falcioni, R.; Ferraresi, V.; Baldini, N.; Biagini, R.; et al. Histone deacetylase inhibitor ITF2357 leads to apoptosis and enhances doxorubicin cytotoxicity in preclinical models of human sarcoma. Oncogenesis 2018, 7, 20. [Google Scholar] [CrossRef]
- Sun, W.; Lv, S.; Li, H.; Cui, W.; Wang, L. Enhancing the Anticancer Efficacy of Immunotherapy through Combination with Histone Modification Inhibitors. Genes 2018, 9, 633. [Google Scholar] [CrossRef] [Green Version]
- Cossío, F.P.; Esteller, M.; Berdasco, M. Towards a more precise therapy in cancer: Exploring epigenetic complexity. Curr. Opin. Chem. Biol. 2020, 57, 41–49. [Google Scholar] [CrossRef]
- Knox, T.; Sahakian, E.; Banik, D.; Hadley, M.; Palmer, E.; Noonepalle, S.; Kim, J.; Powers, J.; Gracia-Hernandez, M.; Oliveira, V.; et al. Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells. Sci. Rep. 2019, 9, 6136. [Google Scholar] [CrossRef] [PubMed]
- Woods, D.M.; Sodré, A.L.; Villagra, A.; Sarnaik, A.; Sotomayor, E.M.; Weber, J. HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade. Cancer Immunol. Res. 2015, 3, 1375–1385. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Terranova-Barberio, M.; Thomas, S.; Ali, N.; Pawlowska, N.; Park, J.; Krings, G.; Rosenblum, M.D.; Budillon, A.; Munster, P.N. HDAC inhibition potentiates immunotherapy in triple negative breast cancer. Oncotarget 2017, 8, 114156–114172. [Google Scholar] [CrossRef] [Green Version]
- García-Guerrero, E.; Gogishvili, T.; Danhof, S.; Schreder, M.; Pallaud, C.; Pérez-Simón, J.A.; Einsele, H.; Hudecek, M. Panobinostat induces CD38 upregulation and augments the antimyeloma efficacy of daratumumab. Blood 2017, 129, 3386–3388. [Google Scholar] [CrossRef] [PubMed]
- García-Guerrero, E.; Götz, R.; Doose, S.; Sauer, M.; Rodríguez-Gil, A.; Nerreter, T.; Kortüm, K.M.; Pérez-Simón, J.A.; Einsele, H.; Hudecek, M.; et al. Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab. Leukemia 2020. [Google Scholar] [CrossRef]
- Shimizu, R.; Kikuchi, J.; Wada, T.; Ozawa, K.; Kano, Y.; Furukawa, Y. HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells. Leukemia 2010, 24, 1760–1768. [Google Scholar] [CrossRef] [Green Version]
- Cuellar, T.L.; Herzner, A.M.; Zhang, X.; Goyal, Y.; Watanabe, C.; Friedman, B.A.; Janakiraman, V.; Durinck, S.; Stinson, J.; Arnott, D.; et al. Silencing of retrotransposons by SETDB1 inhibits the interferon response in acute myeloid leukemia. J. Cell Biol. 2017, 216, 3535–3549. [Google Scholar] [CrossRef] [Green Version]
- Sheng, W.; LaFleur, M.W.; Nguyen, T.H.; Chen, S.; Chakravarthy, A.; Conway, J.R.; Li, Y.; Chen, H.; Yang, H.; Hsu, P.H.; et al. LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade. Cell 2018, 174, 549–563. [Google Scholar] [CrossRef] [Green Version]
- Zhang, H.; Pandey, S.; Travers, M.; Sun, H.; Morton, G.; Madzo, J.; Chung, W.; Khowsathit, J.; Perez-Leal, O.; Barrero, C.A.; et al. Targeting CDK9 Reactivates Epigenetically Silenced Genes in Cancer. Cell 2018, 175, 1244–1258. [Google Scholar] [CrossRef] [Green Version]
- De Lera, A.R.; Ganesan, A. Two-hit wonders: The expanding universe of multitargeting epigenetic agents. Curr. Opin. Chem. Biol. 2020, 57, 135–154. [Google Scholar] [CrossRef]
- Tomaselli, D.; Lucidi, A.; Rotili, D.; Mai, A. Epigenetic polypharmacology: A new frontier for epi-drug discovery. Med. Res. Rev. 2020, 40, 190–244. [Google Scholar] [CrossRef] [PubMed]
- San José-Enériz, E.; Agirre, X.; Rabal, O.; Vilas-Zornoza, A.; Sanchez-Arias, J.A.; Miranda, E.; Ugarte, A.; Roa, S.; Paiva, B.; Estella-Hermoso de Mendoza, A.; et al. Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies. Nat. Commun. 2017, 8, 15424. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rabal, O.; San José-Enériz, E.; Agirre, X.; Sánchez-Arias, J.A.; Vilas-Zornoza, A.; Ugarte, A.; de Miguel, I.; Miranda, E.; Garate, L.; Fraga, M.; et al. Discovery of Reversible DNA Methyltransferase and Lysine Methyltransferase G9a Inhibitors with Antitumoral in Vivo Efficacy. J. Med. Chem. 2018, 61, 6518–6545. [Google Scholar] [CrossRef] [PubMed]
- Zang, J.; Liang, X.; Huang, Y.; Jia, Y.; Li, X.; Xu, W.; Chou, C.J.; Zhang, Y. Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously. J. Med. Chem. 2018, 61, 5304–5322. [Google Scholar] [CrossRef]
- Dong, H.; Yin, H.; Zhao, C.; Cao, J.; Xu, W.; Zhang, Y. Design, Synthesis and Biological Evaluation of Novel Osimertinib-Based HDAC and EGFR Dual Inhibitors. Molecules 2019, 24, 2407. [Google Scholar] [CrossRef] [Green Version]
- Yao, L.; Mustafa, N.; Tan, E.C.; Poulsen, A.; Singh, P.; Duong-Thi, M.D.; Lee, J.X.T.; Ramanujulu, P.M.; Chng, W.J.; Yen, J.J.Y.; et al. Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat. J. Med. Chem. 2017, 60, 8336–8357. [Google Scholar] [CrossRef]
- Wang, N.Y.; Xu, Y.; Xiao, K.J.; Zuo, W.Q.; Zhu, Y.X.; Hu, R.; Wang, W.L.; Shi, Y.J.; Yu, L.T.; Liu, Z.H. Design, synthesis, and biological evaluation of 4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridine derivatives as novel dual-PLK1/BRD4 inhibitors. Eur. J. Med. Chem. 2020, 191, 112152. [Google Scholar] [CrossRef]
- Eijkelenkamp, K.; Osinga, T.E.; Links, T.P.; van der Horst-Schrivers, A.N.A. Clinical implications of the oncometabolite succinate in SDHx-mutation carriers. Clin. Genet. 2020, 97, 39–53. [Google Scholar] [CrossRef] [Green Version]
- Nowicki, S.; Gottlieb, E. Oncometabolites: Tailoring our genes. FEBS J. 2015, 282, 2796–2805. [Google Scholar] [CrossRef]
- Xiao, M.; Yang, H.; Xu, W.; Ma, S.; Lin, H.; Zhu, H.; Liu, L.; Liu, Y.; Yang, C.; Xu, Y.; et al. Inhibition of α-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors. Genes Dev. 2012, 26, 1326–1338. [Google Scholar] [CrossRef] [Green Version]
- Turcan, S.; Rohle, D.; Goenka, A.; Walsh, L.A.; Fang, F.; Yilmaz, E.; Campos, C.; Armida, W.M.; Fabius, A.W.M.; Lu, C.; et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 2012, 483, 479–483. [Google Scholar] [CrossRef] [PubMed]
- Ježek, P. 2-Hydroxyglutarate in Cancer Cells. Antioxid. Redox Signal. 2020, 33, 903–926. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Golub, D.; Iyengar, N.; Dogra, S.; Wong, T.; Bready, D.; Tang, K.; Modrek, A.S.; Placantonakis, D.G. Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics. Front. Oncol. 2019, 9, 417. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Fan, B.; Mellinghoff, I.K.; Wen, P.Y.; Lowery, M.A.; Goyal, L.; Tap, W.D.; Pandya, S.S.; Manyak, E.; Jiang, L.; Liu, G. Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors. Investig. New Drugs. 2020, 38, 433–444. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Popovici-Muller, J.; Lemieux, R.M.; Artin, E.; Saunders, J.O.; Salituro, F.G.; Travins, J.; Cianchetta, G.; Cai, Z.; Zhou, D.; Cui, D.; et al. Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers. ACS Med. Chem. Lett. 2018, 9, 300–305. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Köeferle, A.; Stricker, S.H.; Beck, S. Brave new epigenomes: The dawn of epigenetic engineering. Genome Med. 2015, 7, 59. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Boch, J.; Scholze, H.; Schornack, S.; Landgraf, A.; Hahn, S.; Kay, S.; Lahaye, T.; Nickstadt, A.; Bonas, U. Breaking the code of DNA binding specificity of TAL-type III effectors. Science 2009, 326, 1509–1512. [Google Scholar] [CrossRef]
- Maeder, M.L.; Angstman, J.F.; Richardson, M.E.; Linder, S.J.; Cascio, V.M.; Tsai, S.Q.; Ho, Q.H.; Sander, J.D.; Reyon, D.; Bernstein, B.E.; et al. Targeted DNA demethylation and activation of endogenous genes using programmable TALE-TET1 fusion proteins. Nat. Biotechnol. 2013, 31, 1137–1142. [Google Scholar] [CrossRef] [Green Version]
- Mendenhall, E.M.; Williamson, K.E.; Reyon, D.; Zou, J.Y.; Ram, O.; Joung, J.K.; Bernstein, B.E. Locus-specific editing of histone modifications at endogenous enhancers. Nat. Biotechnol. 2013, 31, 1133–1136. [Google Scholar] [CrossRef] [Green Version]
- Konermann, S.; Brigham, M.D.; Trevino, A.; Hsu, P.D.; Heidenreich, M.; Cong, L.; Platt, R.J.; Scott, D.A.; Church, G.M.; Zhang, F. Optical control of mammalian endogenous transcription and epigenetic states. Nature 2013, 500, 472–476. [Google Scholar] [CrossRef]
- Xie, N.; Zhou, Y.; Sun, Q.; Tang, B. Novel Epigenetic Techniques Provided by the CRISPR/Cas9 System. Stem Cells Int. 2018, 2018, 7834175. [Google Scholar] [CrossRef] [PubMed]
- Jinek, M.; Chylinski, K.; Fonfara, I.; Hauer, M.; Doudna, J.A.; Charpentier, E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 2012, 337, 816–821. [Google Scholar] [CrossRef] [PubMed]
- Yao, S.; He, Z.; Chen, C. CRISPR/Cas9 mediated genome editing of epigenetic factors for cancer therapy. Hum. Gene Ther. 2015, 26, 463–471. [Google Scholar] [CrossRef] [PubMed]
- Syding, L.A.; Nickl, P.; Kasparek, P.; Sedlacek, R. CRISPR/Cas9 Epigenome Editing Potential for Rare Imprinting Diseases: A Review. Cells 2020, 9, 993. [Google Scholar] [CrossRef] [PubMed]
- Perez-Pinera, P.; Kocak, D.D.; Vockley, C.M.; Adler, A.F.; Kabadi, A.M.; Polstein, L.R.; Thakore, P.I.; Glass, K.A.; Ousterout, D.G.; Leong, K.W. RNA-guided gene activation by CRISPR-Cas9-based transcription factors. Nat. Methods 2013, 10, 973–976. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gilbert, L.A.; Larson, M.H.; Morsut, L.; Liu, Z.; Brar, G.A.; Torres, S.E.; Stern-Ginossar, N.; Brandman, O.; Whitehead, E.H.; Doudna, J.A.; et al. CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell 2013, 154, 442–451. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Liu, X.S.; Wu, H.; Ji, X.; Stelzer, Y.; Wu, X.; Czauderna, S.; Shu, J.; Dadon, D.; Young, R.A.; Jaenisch, R. Editing DNA Methylation in the Mammalian Genome. Cell 2016, 167, 233–247. [Google Scholar] [CrossRef] [Green Version]
- McDonald, J.I.; Celik, H.; Rois, L.E.; Fishberger, G.; Fowler, T.; Rees, R.; Kramer, A.; Martens, A.; Edwards, J.R.; Challen, G.A. Reprogrammable CRISPR/Cas9-based system for inducing site-specific DNA methylation. Biol. Open. 2016, 5, 866–874. [Google Scholar] [CrossRef] [Green Version]
- Kang, J.G.; Park, J.S.; Ko, J.H.; Kim, Y.S. Regulation of gene expression by altered promoter methylation using a CRISPR/Cas9-mediated epigenetic editing system. Sci. Rep. 2019, 9, 11960. [Google Scholar] [CrossRef] [Green Version]
- Moses, C.; Nugent, F.; Waryah, C.B.; Garcia-Bloj, B.; Harvey, A.R.; Blancafort, P. Activating PTEN Tumor Suppressor Expression with the CRISPR/dCas9 System. Mol. Ther. Nucleic Acids 2019, 14, 287–300. [Google Scholar] [CrossRef] [Green Version]
- Thakore, P.I.; D’Ippolito, A.M.; Song, L.; Safi, A.; Shivakumar, N.K.; Kabadi, A.M.; Reddy, T.E.; Crawford, G.E.; Gersbach, C.A. Highly specific epigenome editing by CRISPR-Cas9 repressors for silencing of distal regulatory elements. Nat. Methods 2015, 12, 1143–1149. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hilton, I.B.; D’Ippolito, A.M.; Vockley, C.M.; Thakore, P.I.; Crawford, G.E.; Reddy, T.E.; Gersbach, C.A. Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers. Nat. Biotechnol. 2015, 33, 510–517. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wang, H.; Guo, R.; Du, Z.; Bai, L.; Li, L.; Cui, J.; Li, W.; Hoffman, A.R.; Hu, J.F. Epigenetic Targeting of Granulin in Hepatoma Cells by Synthetic CRISPR dCas9 Epi-suppressors. Mol. Ther. Nucleic Acids 2018, 11, 23–33. [Google Scholar] [CrossRef] [Green Version]
- Liu, Q.; Zhao, K.; Wang, C.; Zhang, Z.; Zheng, C.; Zhao, Y.; Zheng, Y.; Liu, C.; An, Y.; Shi, L.; et al. Multistage Delivery Nanoparticle Facilitates Efficient CRISPR/dCas9 Activation and Tumor Growth Suppression In Vivo. Adv. Sci. 2018, 6, 1801423. [Google Scholar] [CrossRef] [PubMed]
Identifier | Study Title | Conditions | Epigenetic Drug | Other Anticancer Drug | Trial Phase | Estimated Enrollment |
---|---|---|---|---|---|---|
NCT04049344 | Decitabine Combined with Oxaliplatin in Patients with Advanced Renal Cell Carcinoma | Metastatic Renal Cell Carcinoma | Decitabine | Oxaliplatin | II | 25 |
NCT04510610 | Camrelizumab Plus Decitabine in Anti-PD-1 Treatment-naive Patients with Relapsed/Refractory Classical Hodgkin Lymphoma | Hodgkin Lymphoma | Decitabine | Camrelizumab | II/III | 100 |
NCT02159820 | Lower Dose Decitabine (DAC)-Primed TC (Carboplatin-Paclitaxel) Regimen in Ovary Cancer | Primary Malignant Neoplasm of Ovary; FIGO Stages II to IV | Decitabine | Carboplatin-Paclitaxel | II/III | 500 |
NCT04353479 | Combined PD1 Inhibitor and Decitabine in Elderly Patients with Relapse and Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia | Decitabine | Camrelizumab (SHR-1210) | II | 29 |
NCT03709550 | Enzalutamide and Decitabine in Treating Patients with Metastatic Castration Resistant Prostate Cancer | Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma in the Soft Tissue and 7 more | Decitabine | Enzalutamide | Ib/II | 21 |
NCT02957968 | Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca | Breast Adenocarcinoma; Estrogen Receptor-Negative Breast Cancer; Estrogen Receptor-Positive Breast Cancer and 10 more | Decitabine | Pembrolizumab followed by standard neoadjuvant chemotherapy | II | 32 |
NCT03295552 | Decitabine Plus Carboplatin in the Treatment of Metastatic TNBC | Metastatic Triple Negative Breast Cancer | Decitabine | Carboplatin | II | 59 |
NCT03094637 | Azacitidine and Pembrolizumab in Treating Patients with Myelodysplastic Syndrome | High Risk Myelodysplastic Syndrome, IPSS Risk Category Intermediate-1, Myelodysplastic Syndrome | Azacitidine | Pembrolizumab | II | 40 |
NCT04490707 | Study of Azacytidine Combined with Lenalidomide As Maintenance Therapy Based on MRD Monitoring in AML | Acute Myeloid Leukemia in Remission | Azacitidine | Lenalidomide | III | 60 |
NCT03019003 | Azacitidine, Durvalumab, and Tremelimumab in Recurrent and/or Metastatic Head and Neck Cancer Patients | Head and Neck Cancer | Azacitidine | Durvalumab, Tremelimumab | IB/II | 59 |
NCT03264404 | Azacitidine and Pembrolizumab in Pancreatic Cancer | Pancreas Cancer | Azacitidine | Pembrolizumab | II | 31 |
NCT03576963 | Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer | Colorectal Adenocarcinoma, CpG Island Methylator Phenotype, Metastatic Microsatellite Stable Colorectal Carcinoma and 5 more | Guadecitabine | Nivolumab | IB/II | 45 |
NCT03308396 | Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer | Advanced Kidney Cancer, Kidney Cancer, Clear Cell Renal Cell Carcinoma | Guadecitabine | Durvalumab | IB/II | 58 |
NCT03913455 | Guadecitabine in Combination with Carboplatin in Extensive Stage Small Cell Lung Cancer | Small Cell Lung Cancer, Extensive-Stage Small Cell Lung Cancer | Guadecitabine | Carboplatin | II | 34 |
Identifier | Study Title | Conditions | Epigenetic Drug | Other Anticancer Drug | Trial Phase | Estimated Enrollment |
---|---|---|---|---|---|---|
NCT04651127 | A Phase Ib/II Trial of Anti-PD-1 Antibody Combined with Histone Deacetylase Inhibitor in Patients with Advanced Cervical Cancer | Cervical Cancer | Chidamide | Toripalimab | Ib/II | 40 |
NCT04562311 | Chidamide with Immunotherapy for Patients with Locally Advanced or Metastatic Urothelial Carcinoma | Bladder Cancer Stage IV | Chidamide | Tislelizumab | II | 43 |
NCT03820596 | Sintilimab in Combination with Chidamide in Refractory and Relapsed ENKTCL | Extranodal natural killer/T cell lymphoma | Chidamide | Sintilimab | I/II | 50 |
NCT03903458 | Tinostamustine and Nivolumab in Advanced Melanoma | Malignant Melanoma | Tinostamustine | Nivolumab | I | 21 |
NCT03024437 | Atezolizumab in Combination with Entinostat and Bevacizumab in Patients with Advanced Renal Cell Carcinoma | Metastatic Cancer, Renal Cancer | Entinostat | Atezolizumab and Bevacizumab | I/II | 62 |
NCT02616965 | A Study to Assess the Feasibility of Romidepsin Combined with Brentuximab Vedotin in Cutaneous T-cell Lymphoma | Cutaneous T-cell Lymphoma (CTCL) | Romidepsin | Brentuximab vedotin | I | 27 |
NCT03939182 | Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma | Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma | Abexinostat | Ibrutinib | I/II | 40 |
NCT03829930 | Combination of Entinostat and Enzalutamide in Advanced Prostate Cancer | Prostate Adenocarcinoma | Entinostat | Enzalutamide | I | 18 |
NCT03848754 | Pracinostat and Gemtuzumab Ozogamicin (PraGO) in Patients with Relapsed/Refractory Acute Myeloid Leukemia | Relapsed Adult AML | Pracinostat | Gemtuzumab Ozogamicin | I | 18 |
NCT03742245 | Olaparib in Combination With Vorinostat in Patients with Relapsed/Refractory and/or Metastatic Breast Cancer | Relapsed/Refractory and/or Metastatic Breast Cancer | Vorinostat | Olaparib | I | 28 |
Drug Name | Year of FDA Approval | |
---|---|---|
DNMTi | Azacitidine | 2004 |
Decitabine | 2006 | |
HDACi | Vorinostat | 2006 |
Romidepsin | 2009 | |
Belinostat | 2014 | |
Panobinostat | 2015 | |
Chidamide * | 2015 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Majchrzak-Celińska, A.; Warych, A.; Szoszkiewicz, M. Novel Approaches to Epigenetic Therapies: From Drug Combinations to Epigenetic Editing. Genes 2021, 12, 208. https://doi.org/10.3390/genes12020208
Majchrzak-Celińska A, Warych A, Szoszkiewicz M. Novel Approaches to Epigenetic Therapies: From Drug Combinations to Epigenetic Editing. Genes. 2021; 12(2):208. https://doi.org/10.3390/genes12020208
Chicago/Turabian StyleMajchrzak-Celińska, Aleksandra, Anna Warych, and Mikołaj Szoszkiewicz. 2021. "Novel Approaches to Epigenetic Therapies: From Drug Combinations to Epigenetic Editing" Genes 12, no. 2: 208. https://doi.org/10.3390/genes12020208
APA StyleMajchrzak-Celińska, A., Warych, A., & Szoszkiewicz, M. (2021). Novel Approaches to Epigenetic Therapies: From Drug Combinations to Epigenetic Editing. Genes, 12(2), 208. https://doi.org/10.3390/genes12020208